Medivir AB announces that a safe dose has been established for treatment with the drug candidate fostroxacitabine bralpamide in combination with Keytruda® in the initial dose escalation part of the company’s 1b/2a study in hepatocellular carcinoma.
Medivir AB announces that a safe dose has been established for treatment with the drug candidate fostroxacitabine bralpamide in combination with Keytruda® in the initial dose escalation part of the company’s 1b/2a study in hepatocellular carcinoma.